“Innovation Pharmaceuticals has submitted a prel

“Innovation Pharmaceuticals has submitted a preliminary summary of Brilacidin’s therapeutic potential as a novel coronavirus treatment to the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA)”

Here are the pharma’s working with BARDA on therapeutics:

Therapeutics

Regeneron Pharmaceuticals is developing multiple monoclonal antibodies that, individually or in combination, could be used to treat COVID-19. Under its expanded agreement with BARDA, Regeneron is leveraging its existing monoclonal antibody discovery platform called VelocImmune, part of the company's VelociSuite technology, to develop therapeutic products to treat COVID-19 infections. VelociSuite was used to develop a promising investigational three-antibody therapeutic, which was deployed to treat Ebola in the most recent outbreak in the Democratic Republic of the Congo, as well as an investigational therapeutic to treat Middle East Respiratory Syndrome coronavirus (MERS-CoV).

Janssen Research & Development is developing treatments for COVID-19 infections. BARDA will collaborate with Janssen to screen library of approved therapeutics as well as investigational therapeutics that have completed some clinical trials where basic safety and pharmacology data are available for these compounds. If screening is promising, candidates then could be considered for further, accelerated development, including assessment in additional clinical studies.

SAb Biotherapeutics is developing a therapeutic, called SAB-185, which is part of a new class of immunotherapies that relies on SAb’s platform technology to produce fully human polyclonal antibodies as the basis for the drug. This technology produces the antibodies without the need for blood donations from people who have recovered from the virus; this approach produces greater quantities of the drug than the traditional human antibody donor methods.

Grifols Shared Services North America, Inc. is developing Convalescent plasma and hyperimmune globulin products that originate from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that specifically target the SARS-CoV-2 virus. To produce convalescent plasma, the donated plasma will be pathogen inactivated and made available in units for infusion as an investigational therapeutic. Grifols will also purify and concentrate the virus-targeting antibodies into an investigational therapeutic called hyperimmune globulin.

Emergent Biosolutions is developing a plasma-based therapeutic treatment for COVID-19 using Human Immune Globulin (HIG). HIG is derived from plasma donated by individuals who have recovered from COVID-19. This plasma contains antibodies that target the SARS-CoV-2 virus. Using their established manufacturing process that supports VIGIV, Anthrasil and other FDA approved products, Emergent will purify and concentrate the virus-targeting antibodies into a drug product that can be administered intravenously as a potential therapeutic.

Genentech is accelerating a phase 3 clinical trial of a novel COVID-19 therapeutic treatment potential treatment of patients with severe cases of COVID-19. BARDA expanded an existing partnership with Genentech to accelerate a Phase 3 clinical trial of Actemra® (tocilizumab) as a potential treatment of patients with severe cases of COVID-19. Currently, Actemra® is approved by the U.S. Food and Drug Administration and in more than 100 countries to treat rheumatoid arthritis or other inflammatory conditions.

https://www.phe.gov/emergency/events/COVID19/...BARDA.aspx